Vitreous Hemorrhage – A Complete Patient Guide

Overview

A vitreous hemorrhage (VH) is bleeding into the vitreous humor—the clear, gel‑like substance that fills the space between the lens and the retina of the eye. The blood can cloud vision, ranging from a few specks to a complete “blackout.” While the condition can affect anyone, it is most common in adults over 50 years of age, especially those with underlying eye disease or systemic vascular disorders.

Key statistics (2023‑2024 data):

• VH accounts for roughly 2–5 % of all ocular emergencies seen in ophthalmology clinics worldwide (Mayo Clinic).
• In the United States, an estimated 150,000–200,000 new cases occur each year, with a higher incidence in patients with proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO) (American Academy of Ophthalmology).
• Approximately 30 % of patients with PDR develop a vitreous hemorrhage at some point during the disease course (NIH, Diabetes Eye Complications Study).

Symptoms

Symptoms can appear suddenly or develop gradually, depending on the amount of blood and its location. Common manifestations include:

• Sudden loss of vision – ranging from a few floating spots (floaters) to a near‑total blackout.
• Floaters – dark, cobweb‑like shapes that drift across the visual field.
• Blurred or hazy vision – the blood scatters light, reducing clarity.
• Red or “blood‑colored” vision – especially when the hemorrhage is dense.
• Photopsia – brief flashes of light, often preceding or accompanying the bleed.
• Pain – usually mild; severe eye pain suggests another cause (e.g., acute angle‑closure glaucoma).
• Peripheral vision loss – if the bleed settles toward the edges of the vitreous.

Because the vitreous is a closed space, the blood does not drain on its own quickly; symptoms may persist for weeks to months if untreated.

Causes and Risk Factors

Primary Causes

• Proliferative Diabetic Retinopathy (PDR) – New, fragile blood vessels grow on the retina and can rupture.
• Retinal Vein Occlusion (RVO) – Blockage of retinal veins leads to leakage and bleeding.
• Trauma – Penetrating or blunt eye injuries can tear retinal vessels.
• Posterior Vitreous Detachment (PVD) – The vitreous pulls away from the retina, sometimes tearing vessels.
• Neovascular Age‑Related Macular Degeneration (nAMD) – Abnormal vessels under the macula bleed.
• Retinal tears or holes – Often associated with PVD; blood can seep into the vitreous.
• Ocular tumors – E.g., choroidal melanoma may bleed into the vitreous.
• Inflammatory conditions – Uveitis or vasculitis can cause hemorrhage.

Risk Factors

• Long‑standing diabetes mellitus (especially with poor glycemic control).
• Hypertension – high blood pressure weakens retinal vessels.
• Age > 50 years – natural vitreous liquefaction and PVD become more common.
• Smoking – accelerates vascular damage and AMD.
• Blood‑thinning medications (e.g., warfarin, clopidogrel) – increase bleeding tendency.
• Coagulopathies (e.g., hemophilia, thrombocytopenia).
• Previous ocular surgery or laser photocoagulation.

Diagnosis

Prompt evaluation by an eye‑care professional (ophthalmologist or retina specialist) is essential.

Clinical Examination

• Visual acuity test – Determines the degree of vision loss.
• Slit‑lamp biomicroscopy – Allows the doctor to view the anterior segment and the vitreous for blood.
• Fundus examination – Direct or indirect ophthalmoscopy to assess the retina for tears, neovascularization, or other pathology.

Imaging & Ancillary Tests

• Optical Coherence Tomography (OCT) – Provides cross‑sectional images of the retina; useful when media opacity limits view.
• Ultrasound B‑scan – Detects retinal detachment, vitreous membranes, or dense hemorrhage when the view is obscured.
• Fluorescein Angiography (FA) – Highlights leaking vessels, especially in diabetic retinopathy or AMD.
• Blood work – CBC, coagulation profile, and HbA1c may be ordered to identify systemic contributors.

Treatment Options

Treatment is tailored to the underlying cause, severity of the bleed, and visual impact.

Observation

Small, non‑vision‑threatening hemorrhages may clear spontaneously within 4–12 weeks. Patients are monitored with serial exams.

Medical Management

• Control of systemic disease – Tight glycemic control (target HbA1c < 7 %) and blood pressure management reduce recurrence (ADA, 2023).
• Intravitreal anti‑VEGF agents – Ranibizumab, aflibercept, or bevacizumab inhibit abnormal vessel growth in PDR, nAMD, and RVO, often reducing the need for surgery (NEI, 2022).
• Intravitreal steroids – Dexamethasone implant for inflammatory or uveitic causes.
• Systemic anticoagulation review – Adjusting or temporarily holding blood thinners under physician guidance.

Surgical Interventions

1. Pars Plana Vitrectomy (PPV) – The gold‑standard for dense or persistent VH. The surgeon removes the vitreous gel and blood, repairs retinal tears, and may apply laser or anti‑VEGF therapy. Visual recovery often begins within weeks.
2. Laser Photocoagulation – Applied after the hemorrhage clears enough to visualize retinal pathology; seals leaking vessels and prevents re‑bleeding.
3. Scleral buckling – Used when a concurrent retinal detachment is present.

Lifestyle & Supportive Measures

• Elevate the head of the bed 30° to reduce intra‑ocular pressure spikes.
• Avoid heavy lifting or straining for 1–2 weeks post‑procedure.
• Use protective eyewear during activities with a risk of eye injury.

Living with Vitreous Hemorrhage

Adapting daily life while vision recovers can be challenging. Below are practical tips:

Vision Aids

• High‑contrast reading glasses or magnifiers.
• Large‑print books, audiobooks, or screen‑reader software.
• Smartphone accessibility features (voice‑over, magnification).

Home Safety

• Keep pathways clear of clutter to prevent trips.
• Use night‑lights in hallways and bathrooms.
• Arrange frequently used items within easy reach.

Follow‑up Care

• Attend all scheduled ophthalmology appointments; early detection of re‑bleeding or retinal detachment is critical.
• Report any new floaters, flashes, or sudden vision changes immediately.
• Maintain a log of visual symptoms to discuss with your doctor.

Emotional Well‑Being

Sudden vision loss can cause anxiety or depression. Consider:

• Joining support groups (e.g., American Foundation for the Blind).
• Speaking with a mental‑health professional.
• Practicing relaxation techniques to manage stress, which can affect blood pressure.

Prevention

While some causes (e.g., trauma) are avoidable, many risk factors are modifiable.

• Control diabetes – Regular monitoring, diet, exercise, and medication adherence.
• Manage hypertension – Aim for <130/80 mmHg or lower per ACC/AHA guidelines.
• Quit smoking – Reduces risk of AMD and vascular disease.
• Regular eye exams – Annual dilated retinal exams for diabetics and yearly checks after age 50.
• Protective eyewear – Safety glasses for sports, home improvement, or occupational hazards.
• Medication review – Discuss with your physician the necessity of anticoagulants and possible alternatives.

Complications

If left untreated or inadequately managed, vitreous hemorrhage can lead to serious sequelae:

• Permanent vision loss – Due to prolonged retinal ischemia or scarring.
• Tractional retinal detachment – Fibrous tissue contracts, pulling the retina away.
• Neovascular glaucoma – New vessels grow on the iris, obstructing fluid outflow and raising intra‑ocular pressure.
• Recurrent hemorrhage – Especially in uncontrolled diabetic retinopathy.
• Macular edema – Fluid accumulation at the central retina, further blurring vision.

When to Seek Emergency Care

References

• Mayo Clinic. “Vitreous Hemorrhage.” Updated 2023. https://www.mayoclinic.org
• American Academy of Ophthalmology. “Vitreous Hemorrhage Clinical Guidelines.” 2022.
• National Institutes of Health (NIH). “Diabetic Retinopathy Clinical Research.” 2023.
• Centers for Disease Control and Prevention (CDC). “Diabetes and Vision Loss.” 2022.
• Cleveland Clinic. “Anti‑VEGF Therapy for Eye Disease.” 2024.
• World Health Organization (WHO). “Global Report on Vision 2022.”
• American Diabetes Association. “Standards of Care in Diabetes—2023.”
• National Eye Institute (NEI). “Retinal Vein Occlusion.” 2022.